<DOC>
	<DOCNO>NCT00059839</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . It yet know combination chemotherapy vinblastine effective combination chemotherapy vincristine treat advance anaplastic large cell lymphoma . PURPOSE : Randomized phase III trial compare effectiveness two combination chemotherapy regimens either vinblastine vincristine treat patient newly diagnose advanced anaplastic large cell lymphoma .</brief_summary>
	<brief_title>Comparison Two Combination Chemotherapy Regimens With Either Vincristine Vinblastine Treating Patients With Advanced Anaplastic Large Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy consolidation chemotherapy regimen comprise doxorubicin prednisone combination vincristine v vinblastine , term event-free survival , patient advance anaplastic large cell lymphoma . - Compare overall survival patient treat regimen . - Compare toxic effect regimens patient . - Correlate biological tumor characteristic outcome patient treat regimen . OUTLINE : This randomize , multicenter study . Patients randomized enrollment receive either Standard APO regimen consolidation regimen include vinblastine ( VBL ) . - Induction therapy : All Patients receive doxorubicin IV 15 minute day 1 22 ; vincristine IV day 1 , 8 , 15 , 22 , 29 ; oral prednisone 3 time daily day 1-28 ; intrathecal ( IT ) methotrexate day 1 , 8 , 22 ( patient central nervous system ( CNS ) disease diagnosis receive additional methotrexate IT day 15 , 29 , 36 ) . Patients undergo restaging Induction consolidation therapy start day 43 . All patient complete response ( CR ) , complete response unconfirmed ( CRu ) partial response ( PR ) proceed Consolidation base CT MRI scan end induction ( week 6 ) . All patient remove protocol therapy follow meet criterion study . Follow-up data require unless consent withdrawn . - Standard APO ( Arm I ) : Patients receive course-specific regimen without vinblastine . - Courses 1-3 : Patients receive doxorubicin IV 15 minute , vincristine IV , methotrexate IT day 1 oral prednisone three time daily oral mercaptopurine daily day 1-5 . - Courses 4-5 : Patients receive doxorubicin , vincristine , prednisone , mercaptopurine course 1-3 . - Courses 6-15 : Patients receive vincristine , prednisone , mercaptopurine course 1-3 methotrexate IV day 1 . - Consolidation vinblastine ( Arm II ) : Patients receive course-specific regimen include vinblastine . - Courses 1-3 : Patients receive doxorubicin , methotrexate IT , prednisone , mercaptopurine arm I vinblastine IV 1 minute day 1 , 8 , 15 . - Courses 4-5 : Patients receive doxorubicin , prednisone , mercaptopurine arm I vinblastine arm II ( course 1-3 ) . - Courses 6-15 : Patients receive prednisone mercaptopurine arm I , vinblastine arm II ( course 1-3 ) , methotrexate IV day 1 . In arm course , treatment repeat every 21 day 15 course absence disease progression unacceptable toxicity . Patients follow monthly 1 year , every 3 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 200-250 patient ( 100-125 per treatment arm ) accrue study within 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose advanced anaplastic large cell lymphoma Cluster differentiation antigen 30 ( CD30+ ) Murphy stage III IV No Bcell large cell lymphoma No disease limit skin ( regardless widespread ) PATIENT CHARACTERISTICS : Age Under 21 Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) less 2.5 time ULN ( unless due lymphoma ) Renal Not specify Cardiovascular Shortening fraction ( SF ) least 27 % echocardiogram OR Ejection fraction ( EF ) least 50 % radionuclide angiogram Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Prior steroid management mediastinal mass allow Radiotherapy Prior limiteddose radiotherapy mediastinal mass allow Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>anaplastic large cell lymphoma</keyword>
</DOC>